SCS-C000495
8''R,9''-diolversicolactone B
Pathway: Shikimates and Phenylpropanoids
Superclass: Lignans
Class: Neolignans
Chemical Structure
Loading 3D structure...
3D conformers are computationally generated from SMILES by RDKit for visualization and download; they are not experimental crystal or NMR structures.
Source Information
Aspergillus terreus
(mangrove endophytic fungus)
Kingdom
Fungi
Phylum
Ascomycota
Class
Eurotiomycetes
Order
Eurotiales
Family
Aspergillaceae
Genus
Aspergillus
Species
Aspergillus terreus
South China Sea
DOI:
10.1039/c8ra01840e
· RSC Advances
Drug-likeness (Lipinski Ro5)
Molecular Weight
456.5 Da
Threshold ≤ 500
ALogP
2.44
Threshold ≤ 5
H-Bond Donors
4
Threshold ≤ 5
H-Bond Acceptors
8
Threshold ≤ 10
Passes Lipinski Rule of Five — drug-like candidate
Chemical Properties
Molecular Formula:
C25H28O8
Molecular Weight:
456.4910 Da
SMILES:
COC(=O)[C@@]1(Cc2ccc(CC[C@@H](O)C(C)(C)O)c(O)c2)OC(=O)C(O)=C1c1ccccc1
InChIKey:
STDLBUQIZPWSLB-CLOONOSVSA-N
InChI:
InChI=1S/C25H28O8/c1-24(2,31)19(27)12-11-16-10-9-15(13-18(16)26)14-25(23(30)32-3)20(21(28)22(29)33-25)17-7-5-4-6-8-17/h4-10,13,19,26-28,31H,11-12,14H2,1-3H3/t19-,25+/m1/s1
Calculated Properties
ALogP:
2.437 lipophilicity
TPSA:
133.52 Ų polar surface area
H-Bond Donors:
4
H-Bond Acceptors:
8
Rotatable Bonds:
8
Ring Count:
3
(2 aromatic)
Chiral Centers:
2
Fsp³:
0.3600 fraction sp³ carbon
Database Information
Compound ID:
SCS-C000495
NPClassifier Pathway:
Shikimates and Phenylpropanoids
NPClassifier Superclass:
Lignans
NPClassifier Class:
Neolignans
Glycoside:
No
NPClassifier Status:
Classified
External Links:
General chemistry
Natural product databases
Biological Activity Data
Activity values are displayed only when a quantitative or clearly reported result is available.
Tested organisms, cell lines and molecular targets are shown under Target / model.
| Activity | Assay | Target / model | Result | Reference |
|---|---|---|---|---|
| Anti-inflammatory | inhibition | RAW264.7 mouse macrophages | inhibition of NO production | 10.1039/c8ra01840e RSC Advances |